Search results
Showing 151 to 200 of 298 results for breast cancer
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
Early value assessment (EVA) guidance on artificial intelligence technologies to aid contouring for radiotherapy treatment planning in people having external be...
View recommendations for HTE11Show all sections
Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued [GID-TAG403]
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued [GID-TA10066]
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued [GID-TA10570]
This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Awaiting development [GID-TA11339] Expected publication date: TBC
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Awaiting development [GID-TA11110] Expected publication date: TBC
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued [GID-TA10295]
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued [GID-TA10309]
Microwave ablation for primary or metastatic cancer in the lung (IPG716)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for IPG716Show all sections
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued [GID-TA11261]
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued [GID-TA10539]
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued [GID-TA11178]
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development [GID-TA11022] Expected publication date: TBC
Discontinued [GID-TAG390]
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued [GID-TA10327]
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Introduction
- List of quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...
specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...
specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...
In development [GID-TA10261] Expected publication date: TBC
Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...
Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
Key points: cancer screening An important element of learning disability health checks is making sure that routine healthcare, such as...
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued [GID-TAG417]
The section of the NICE impact lung cancer report looking at how lung cancer is detected.
combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012 Other